Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-08-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于2024年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Kunming Pharmaceutical Group Co., Ltd. regarding the management and actual use of funds raised in the first half of 2024. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange concerning the management and use of raised funds. The content includes detailed financial figures about the amounts raised through various stock issuances (initial public offering, additional issuance, and private placement), the timing of fund receipts, usage amounts in previous and current years, balances, investment projects funded by the raised capital, and compliance with regulatory requirements. The document also discusses the establishment and execution of fund management systems, the use of special accounts for raised funds, and the investment of idle funds in financial products. This type of document is a specialized report on the use and management of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). It is not a full annual or interim report, nor is it an announcement or certification. The length and detail confirm it is a substantive report rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2024-08-22 Chinese
昆药集团十届三十次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the decisions made at the 30th meeting of the 10th board of directors, including approval of the 2024 semi-annual report and other corporate governance matters such as appointment of a vice president and asset impairment provisions. The document includes voting results and references to other announcements and reports but does not contain the full semi-annual report or detailed financial statements itself. The document is relatively short (1734 characters) and serves as an official announcement of board decisions rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it announces board resolutions and management appointments.
2024-08-22 Chinese
昆药集团2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2024年半年度报告摘要" which translates to "2024 Semi-Annual Report Summary". It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and cash flow figures. It also includes management discussion and analysis of business operations, strategic initiatives, and market conditions for the first half of 2024. The document is about 9,154 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or a certification. The content aligns with the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, the document should be classified as an Interim / Quarterly Report (IR).
2024-08-22 Chinese
昆药集团关于联合控股股东华润三九召开2024年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about a scheduled half-year 2024 performance explanation meeting (业绩说明会) to be held online by Kunming Pharmaceutical Corporation and its controlling shareholder. It mentions the date, time, format, and participation details for the meeting, which is intended to discuss the company's 2024 half-year operating results and financial indicators. The document does not contain actual financial statements or detailed financial analysis but serves as a notice for the upcoming investor presentation event. According to the filing definitions, this type of document is best classified as an Investor Presentation (IP) because it focuses on informing investors about a detailed presentation on financials and business performance, even though the actual presentation will occur later. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is IP with high confidence.
2024-08-22 Chinese
昆药集团关于2024年半年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the provision for asset impairment for the half-year period ending June 30, 2024. It details the basis and amounts of impairment provisions for accounts receivable, inventory, and other assets, as well as the impact on the company's profit. The document includes opinions from the Audit and Risk Control Committee and the Supervisory Board endorsing the impairment provisions. The content is focused on a specific accounting adjustment for a half-year period and does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report. Instead, it is a regulatory announcement about the impairment provision decision made by the board. The document length is 2232 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), as it is a compliance announcement about accounting provisions rather than a full financial report or earnings release.
2024-08-22 Chinese
昆药集团关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (毕马威华振会计师事务所) for auditing services for the fiscal year 2024. It details the qualifications, independence, and past performance of the accounting firm, as well as the approval process involving the board and shareholders. There are no actual financial statements or audit reports included, only information about the appointment process and firm credentials. The document is relatively short (2997 characters) and serves as a formal announcement rather than the audit report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about auditor appointment and not the audit report or annual report itself.
2024-08-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.